Enhertu comes as a powder in a single-dose vial. Each vial contains 100 milligrams (mg) of Enhertu. A healthcare professional will mix the powder with liquid to make a liquid solution.

Enhertu is supplied in a single-dose vial containing 100mg of lyophilized powder for reconstitution and further dilution prior to IV infusion. Patients should be selected for treatment with ...

Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate (ADC) bearing a deruxtecan (TOP1 inhibitor) warhead, was developed by Japanese pharmaceutical company Daichi Sankyo. A ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the DESTINY-Breast03 trial, as well as several other indications, including HR ...

The companies said Enhertu is the first HER2-directed therapy to show a strong tumour response in this population, which accounts for 2% to 4% of all NSCLC cases. Image. Phil Taylor.

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

TOKYO& BASKING RIDGE, N.J.---- Daiichi Sankyo and AstraZeneca have been awarded The Galien Foundation 2024 Prix Galien USA Award for Best Biotechnology Product for ENHERTU ®. ENHERTU is a ...

AstraZeneca and Daiichi Sankyo’ s ENHERTU ® has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor- positive, HER2-low or HER2-ultralow ...

The safety of ENHERTU was evaluated in 347 adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who received ENHERTU 5.4 mg/kg intravenously once every 3 weeks in ...

ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 ...

Among patients with human epidermal growth factor receptor 2 (HER2, IHC 3+ or IHC 2+/ISH+) positive unresectable and/or metastatic gastric or gastroesophageal cancer, Enhertu (trastuzumab deruxtecan) ...